Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia

Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia

Bibliographic Details
Main Authors:	Pashos, Chris L., Larholt, Kay, Fraser, Kimberly A., McKenzie, R. Scott, Senbetta, Mekré, Piech, Catherine Tak
Format:	Online
Language:	English
Published:	Springer-Verlag 2011
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223590/

Similar Items

Erythropoiesis-stimulating Agents and Anemia in Patients with Non-dialytic Chronic Kidney Disease
by: Kim, Sun Moon, et al.
Published: (2016)

Hemoglobin decline in cancer patients receiving chemotherapy without an erythropoiesis-stimulating agent
by: Pirker, Robert, et al.
Published: (2012)

Erythropoiesis-stimulating agents for the treatment of chemotherapy-induced anemia: comparisons from real-world clinical experience
by: Rodriguez Garzotto, Analia, et al.
Published: (2014)

Erythropoiesis-stimulating agents for the treatment of chemotherapy-induced anemia: comparisons from real-world clinical experience [Corrigendum]
Published: (2014)

Pharmacovigilance in practice: erythropoiesis-stimulating agents
by: Hedenus, Michael, et al.
Published: (2014)

Anemia and iron deficiency in COPD patients: prevalence and the effects of correction of the anemia with erythropoiesis stimulating agents and intravenous iron
by: Silverberg, Donald S, et al.
Published: (2014)

Erythropoiesis stimulating agents: approaches to modulate activity
by: Sinclair, Angus M
Published: (2013)

Protective roles of erythropoiesis-stimulating proteins in chronic heart failure with anemia
by: ZHOU, SHUQIN, et al.
Published: (2014)

Effects of erythropoiesis-stimulating agents on heart failure patients with anemia: a meta-analysis
by: Zhang, Hengliang, et al.
Published: (2016)

Zebrafish erythropoiesis and the utility of fish as models of anemia
by: Kulkeaw, Kasem, et al.
Published: (2012)

Timing-adjusted iron dosing enhances erythropoiesis-stimulating agent-induced erythropoiesis response and iron utilization
by: Tomoyuki Kawano, et al.
Published: (2017-05-01)

Associations among Erythroferrone and Biomarkers of Erythropoiesis and Iron Metabolism, and Treatment with Long-Term Erythropoiesis-Stimulating Agents in Patients on Hemodialysis
by: Honda, Hirokazu, et al.
Published: (2016)

Budget impact analysis on erythropoiesis–stimulating agents use for the management of chemotherapy-induced anaemia in Greece
by: Nikolaidi, Eleftheria, et al.
Published: (2013)

Erythropoiesis-stimulating agents: benefits and risks in supportive care of cancer
by: Melosky, B.L.
Published: (2008)

Dosing of Erythropoiesis-Stimulating Agents Can Be Reduced by a New Administration Regimen
by: Stefánsson, Bergur V., et al.
Published: (2011)

Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer
by: Aapro, M, et al.
Published: (2012)

Quantitative assessment of minimal effective concentration of erythropoiesis-stimulating agents
by: Yan, X, et al.
Published: (2013)

Erythropoiesis-stimulating agent resistance and mortality in hemodialysis and peritoneal dialysis patients
by: Suttorp, Marit M, et al.
Published: (2013)

Effect of Erythropoiesis-Stimulating Agents on Blood Pressure in Pre-Dialysis Patients
by: Suttorp, Marit M., et al.
Published: (2013)

Resistance to Erythropoiesis-Stimulating Agents Is Associated with Arterial Microcalcification in Early Hemodialysis Patients
by: Won, Hye Sung, et al.
Published: (2014)

Regulation of platelet count by erythropoiesis-stimulating agents – iron axis in hemodialysis patients
by: Koike, Kiyomi, et al.
Published: (2016)

A budget impact analysis of the introduction of erythropoiesis stimulating agent subsequent entry biologics for the treatment of anemia of chronic kidney disease in Canada
by: Tsao, Nicole W, et al.
Published: (2014)

Defective erythropoiesis in bone marrow is a mechanism of anemia in children with cancer.
by: Kim, MunHee, et al.
Published: (2002)

A critical role for mTORC1 in erythropoiesis and anemia
by: Knight, Zachary A, et al.
Published: (2014)

Effects of erythropoiesis-stimulating agents on survival and other outcomes in patients with lymphoproliferative malignancies: a study-level meta-analysis
by: Hedenus, Michael, et al.
Published: (2012)

Comparison between short- and long-acting erythropoiesis-stimulating agents in hemodialysis patients: target hemoglobin, variability, and outcome
by: Bernieh, Bassam, et al.
Published: (2014)

A Biomathematical Model of Human Erythropoiesis under Erythropoietin and Chemotherapy Administration
by: Schirm, Sibylle, et al.
Published: (2013)

Association between high-dose erythropoiesis-stimulating agents, inflammatory biomarkers, and soluble erythropoietin receptors
by: Inrig, Jula K, et al.
Published: (2011)

Implications of a Reduction in the Hemoglobin Target in Erythropoiesis-Stimulating Agent-Treated Hemodialysis Patients
by: Nguyen, Timothy V., et al.
Published: (2011)

Utilization Patterns of IV Iron and Erythropoiesis Stimulating Agents in Anemic Chronic Kidney Disease Patients: A Multihospital Study
by: Joshi, Avani D., et al.
Published: (2012)

Hepcidin-25 in Chronic Hemodialysis Patients Is Related to Residual Kidney Function and Not to Treatment with Erythropoiesis Stimulating Agents
by: van der Weerd, Neelke C., et al.
Published: (2012)

Absorption, distribution, metabolism and excretion of peginesatide, a novel erythropoiesis-stimulating agent, in rats
by: Woodburn, Kathryn W., et al.
Published: (2011)

Reduced use of erythropoiesis-stimulating agents and intravenous iron with ferric citrate: a managed care cost-offset model
by: Mutell, Richard, et al.
Published: (2013)

Staff Time and Motion Assessment for Administration of Erythropoiesis-Stimulating Agents: A Two-Phase Pilot Study in Clinical Oncology Practices
by: Reitan, John F., et al.
Published: (2013)

Should we adjust erythropoiesis-stimulating agent dosage to postdialysis hemoglobin levels? A pilot study
by: Castillo, Nieves, et al.
Published: (2012)

Erythropoiesis-stimulating Agent Use among Patients with Lupus Nephritis Approaching End-stage Renal Disease
by: Gómez-Puerta, José A, et al.
Published: (2013)

Factors precipitating erythropoiesis‐stimulating agent responsiveness in a European haemodialysis cohort: case‐crossover study†
by: Gillespie, Iain A., et al.
Published: (2015)

Ferric pyrophosphate citrate administered via dialysate reduces erythropoiesis-stimulating agent use and maintains hemoglobin in hemodialysis patients
by: Gupta, Ajay, et al.
Published: (2015)

Association of plasma F2-isoprostanes and isofurans concentrations with erythropoiesis-stimulating agent resistance in maintenance hemodialysis patients
by: Rivara, Matthew B., et al.
Published: (2015)

A meta-analysis of the relative doses of erythropoiesis-stimulating agents in patients undergoing dialysis
by: Bonafont, Xavier, et al.
Published: (2009)